12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Intranasal sumatriptan powder: Phase III data

The double-blind Phase III TARGET trial in 212 patients showed that 16 mg intranasal OptiNose sumatriptan met the primary of increasing the proportion of patients achieving headache relief at 2 hours post-treatment vs....

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >